The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Open accessAbstract
Therapeutic blocking of the PD1 pathway results in significant tumor responses, but resistance is common. We demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-independent resistance to immune checkpoint blockade (ICB) and to combinations such as radiation plus anti-CTLA4. Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic changes and augments expression of interferon-stimulated genes and ligands for multiple T cell inhibitory receptors. Both type I and II interferons maintain this resistance program. Crippling the program genetically or pharmacologically interferes with multiple inhibitory pathways and expands distinct T cell populations with improved function despite expressing markers of severe exhaustion. Consequently, tumors resistant to multi-agent ICB are rendered responsive to ICB monotherapy. Finally, we observe that biomarkers for interferon-driven resistance associate with clinical progression after anti-PD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive resistance and inhibition of the interferon response bypasses requirements for combinatorial ICB therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IFN γ and TNF α are key effector cytokines that contribute to anti-tumour immune responses 9,11,27-30 , and genes associated with IFN and TNF signaling pathways contribute to immune evasion 4,9,29 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Chronic IFN signaling can also promote an immune suppressive environment126.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [126]
In the citing paper
“The expression of PD-L1 and MHC II, which may cause exhaustion by binding to T-cell programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3), respectively, is regulated by tumor interferon (IFN) signaling.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“In solid tumors, a tumor IFN–stimulated gene signature termed ISG.RS is associated with a multigenic program of T-cell exhaustion and worse outcomes after immune checkpoint blockade.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“One part of this program is to increase tumor expression of multiple T-cell ligands that lead to exhaustion of T cells infiltrating the TME.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“When tumors express a gene signature (ISG.RS) consisting of genes coordinately activated by multiple types of IFN, a multigenic therapy resistance program is activated.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“Recently, the Minn group elucidated how chronic IFN signaling mediates immunosuppression and resistance to radiation and immune checkpoint inhibitor therapy in solid tumors.2,24,54”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“interferon signaling is of central importance to antitumor immune response43.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Flagged first, then by citations
1 of the 42 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–600 of 1,000
Guo, X., Cui, T., Sun, L., Fu, Y., Cheng, C., Wu, C., Zhu, Y., Liang, S., Liu, Y., Zhou, S., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01432-0 · Cited by 28
Liu, F., Ding, Y., Xu, Z., Hao, X., Pan, T., Miles, G. E., Wang, S., Wu, Y.-H., Liu, J., Bado, I., et al. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.100888 · Cited by 32
Yang, W., Jiang, C., Xia, W., Ju, H., Jin, S., Liu, S., Zhang, L., Ren, G., Ma, H., Ruan, M., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.052 · Cited by 27
Yang, J., Zhang, Y., & Song, H. (2019) · Aging · doi:10.18632/aging.102197 · Cited by 27
DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors
Chung, J., Ramani, V., Kobayashi, M., Fattah, F. J., Popat, V., Zhang, S., Cruz, P. D., Gerber, D. E., & Ariizumi, K. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2360 · Cited by 28
Impact of checkpoint blockade on cancer vaccine–activated CD8+ T cell responses
Santos, P. M. L., Adamik, J., Howes, T. R., Du, S. W., Vujanovic, L. N., Warren, S. E., Gambotto, A. A., Kirkwood, J. M., & Butterfield, L. H. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191369 · Cited by 27
The Paradoxical Roles of Inflammation during PD-1 Blockade in Cancer
Hill, M., Segovia, M., Russo, S., Girotti, M. R., & Rabinovich, G. A. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.09.003 · Cited by 26
PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis
Linares, J. F., Zhang, X., Martínez-Ordóñez, A., Durán, Á., Kinoshita, H., Kasashima, H., Nakanishi, N., Nakanishi, Y., Carelli, R., Cappelli, L. V., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.039 · Cited by 28
Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?
Gazaille, C., Sicot, M., Saulnier, P., Eyer, J., & Bastiat, G. (2021) · Frontiers in Medical Technology · doi:10.3389/fmedt.2021.791596 · Cited by 31
Wang, Z., Lu, C., Zhang, K., Lin, C., Wu, F., Tang, X., Wu, D., Dou, Y., Han, R., Wang, Y., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.780200 · Cited by 29
Yang, L., Dong, X., Liu, Z., Tan, J., Huang, X., Wen, T., Qu, H., & Wang, Z. (2022) · eLife · doi:10.7554/elife.79811 · Cited by 27
Hargadon, K. M. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04689-9 · Cited by 30
Liu, Y., Xu, C., Zhang, L., Xu, G., Yang, Z., Xiang, L., Jiao, K., Chen, Z., Zhang, X., & Liu, Y. (2024) · Science Advances · doi:10.1126/sciadv.adi7764 · Cited by 27
IFN Signaling and ICB Resistance: Time is on Tumor’s Side
López‐Soto, A., Gonzalez, S. R., & Folgueras, A. R. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.01.004 · Cited by 26
Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future
Huang, Y., Gu, Z., Fan, Y., Zhai, G., Zhao, X., Sun, Q., Shi, Y., & Lin, G. (2019) · Purinergic Signalling · doi:10.1007/s11302-018-9641-4 · Cited by 26
Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy
Apollonio, B., Ioannou, N., Papazoglou, D., & Ramsay, A. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626818 · Cited by 27
Interferon regulatory factor transcript levels correlate with clinical outcomes in human glioma
Lei, J., Zhou, M.-H., Zhang, F.-C., Wu, K., Liu, S., & Niu, H. (2021) · Aging · doi:10.18632/aging.202915 · Cited by 26
Marciscano, A. E. E., Walker, J. M., McGee, H. M., Kim, M. M., Kunos, C. A., Monjazeb, A. M., Shiao, S. L., Tran, P. T., & Ahmed, M. M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0317-y · Cited by 27
Molecular background of skin melanoma development and progression: therapeutic implications
Olbryt, M. (2019) · Advances in Dermatology and Allergology · doi:10.5114/ada.2019.84590 · Cited by 27
Purbey, P. K., Seo, J., Paul, M. K., Iwamoto, K. S., Daly, A. E., Feng, A., Champhekar, A. S., Langerman, J., Campbell, K. M., Schaue, D., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114289 · Cited by 27
Biomolecular condensates and disease pathogenesis
Ruan, K., Bai, G., Fang, Y., Li, D., Li, T., Liu, X., Lu, B., Lü, Q., Songyang, Z., Sun, S., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2661-3 · Cited by 28
IFN-γ–inducible antiviral responses require ULK1-mediated activation of MLK3 and ERK5
Saleiro, D., Blyth, G. T., Kościuczuk, E. M., Ozark, P. A., Majchrzak-Kita, B., Arslan, A. D., Fischietti, M., Reddy, N. K., Horvath, C. M., Davis, R. J., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aap9921 · Cited by 25
Salewski, I., Gladbach, Y. S., Kuntoff, S., Irmscher, N., Hahn, O., Junghanß, C., & Maletzki, C. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02570-y · Cited by 25
Hii, L., Chung, F. F., Mai, C., Ng, P. Y., & Leong, C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.748470 · Cited by 25
Immune evasion and therapeutic opportunities based on natural killer cells
Zhang, J., Guo, F., Li, L., Zhang, S., & Wang, Y. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.03.07 · Cited by 26
APOBEC3 Mediates Resistance to Oncolytic Viral Therapy
Huff, A. L., Wongthida, P., Kottke, T. J., Thompson, J., Driscoll, C. B., Schuelke, M. R., Shim, K. G., Harris, R. S., Molan, A. M., Pulido, J. S., et al. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.08.003 · Cited by 25
Tong, Y., Zhou, L., Yang, L., Guo, P., Cao, Y., Qin, F. X.-F., & Liu, J. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.062 · Cited by 24
Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer
Jalalvand, M., Darbeheshti, F., & Rezaei, N. (2021) · Immunotherapy · doi:10.2217/imt-2020-0283 · Cited by 26
Mizuhara, K., Shimura, Y., Tsukamoto, T., Kanai, A., Kuwahara‐Ota, S., Yamaguchi, J., Muramatsu, A., Okamoto, H., Katsuragawa‐Taminishi, Y., Kawaji‐Kanayama, Y., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19049 · Cited by 24
Singh, S. D., Singh, N., Baranwal, M., Sharma, S., Devi, S., & Kumar, S. (2023) · 3 Biotech · doi:10.1007/s13205-023-03826-2 · Cited by 24
Gao, Y. J., Wang, Z., Jin, X., Wang, X., Tao, Y., Huang, S., Wang, Y., Hua, Y., Guo, X., Xu, J., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400538 · Cited by 24
Xu, K., Gu, T., Su, K., Liu, X., He, B., He, J., Chi, H., Zhou, X., Liu, H., Xiao, R., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02914-4 · Cited by 26
Advances in Cancer Treatment Through Nanotheranostics and Emerging Therapies
Akpe, V., & Cock, I. E. (2025) · Journal of Nanotheranostics · doi:10.3390/jnt6040029 · Cited by 27
JAK inhibition in PD-1 immunotherapy and tumor microenvironment
Liu, Y., Liu, J., Chu, H., Lu, Z., Xu, S., Qin, Y., Zhao, L., & Zhang, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1790936 · Cited by 29
IFN-γ in tissue-immune homeostasis and antitumor immunity
Kwon, B. (2017) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.95 · Cited by 24
Immunogenic Cell Death Driven by Radiation—Impact on the Tumor Microenvironment
Yamazaki, T., Vanpouille‐Box, C., Demaria, S., & Galluzzi, L. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_10 · Cited by 28
Resistance mechanisms to checkpoint inhibitors
Weiss, S. A., & Sznol, M. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.001 · Cited by 24
Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer
Clark, C. A., & Yang, E. S.-H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703802 · Cited by 24
Beck, R. J., Slagter, M., & Beltman, J. B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3147 · Cited by 24
Armitage, J. D., Newnes, H. V., McDonnell, A. M., Bosco, A., & Waithman, J. C. (2021) · Cells · doi:10.3390/cells10010056 · Cited by 26
CAR-T failure: beyond antigen loss and T cells
Strati, P., & Neelapu, S. S. (2021) · Blood · doi:10.1182/blood.2020010462 · Cited by 25
Yang, X., Deng, Y., Ye, Y., Meng, J., Su, M., Wei, W., Qin, Y., Zhang, H., Tian, Y., Deng, S., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2982 · Cited by 25
Acquired resistance to immunotherapy in solid tumors
Verdys, P., Johansen, A. Z., Gupta, A. K., Presti, M., Dionisio, E., Madsen, D. H., Fontecedro, A. C., & Donia, M. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.03.010 · Cited by 23
Pitroda, S. P., Stack, M. E., Liu, G.-F., Song, S.-S., Chen, L. L., Liang, H. L., Parekh, A. D., Huang, X., Roach, P., Posner, M. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0667 · Cited by 23
Hattori, N., & Nakamaki, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092057 · Cited by 22
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
Fenton, S. E., Sosman, J. A., & Chandra, S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.28 · Cited by 28
Senescence and Aging: Does It Impact Cancer Immunotherapies?
Maggiorani, D., & Beausejour, C. M. (2021) · Cells · doi:10.3390/cells10071568 · Cited by 25
Yang, K., Shi, Y., Luo, M., Mao, M., Zhang, X., Chen, C., Liu, Y., He, Z., Liu, Q., Wang, W., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2030020 · Cited by 21
Combination of NKG2A and PD-1 Blockade Improves Radiotherapy Response in Radioresistant Tumors
Battaglia, N. G., Murphy, J. D., Uccello, T. P., Hughson, A. L., Gavras, N. W., Caldon, J. J., Gerber, S. A., & Lord, E. M. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100044 · Cited by 23
Huang, Y., Chen, Z., Shen, G., Fang, S., Zheng, J., Chi, Z., Zhang, Y., Zou, Y., Gan, Q., Liao, C., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2318815 · Cited by 23
Tuong, Z. K., Nöske, K., Kuo, P., Bashaw, A. A., Teoh, S. M., & Frazer, I. H. (2017) · Papillomavirus Research · doi:10.1016/j.pvr.2017.10.001 · Cited by 24
Gerner, M. C., Niederstaetter, L., Ziegler, L. S., Bileck, A., Slany, A., Janker, L., Schmidt, R. L. J., Gerner, C., Favero, G. D., & Schmetterer, K. G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00727 · Cited by 23
Informatics for cancer immunotherapy
Hammerbacher, J., & Snyder, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx682 · Cited by 23
Context-dependent impact of type I interferon signaling in cancer
Ruiz-Iglesias, A., Guilbaud, E., Galluzzi, L., & Mañes, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02495-4 · Cited by 25
Cancer immune resistance: can theories converge?
Lu, R. O., Turan, T., Samayoa, J. A., & Marincola, F. M. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170060 · Cited by 22
Immunotherapy – Strategies for Expanding Its Role in the Treatment of All Major Tumor Sites
Sanghera, C., & Sanghera, R. (2019) · Cureus · doi:10.7759/cureus.5938 · Cited by 23
Tran, T.-A.-T., Kim, Y.-H., Duong, T.-H.-O., Jung, S., Kim, I., Moon, K., Jang, W., Lee, H., Lee, J., & Jung, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01165 · Cited by 22
Padmanabhan, S., Gaire, B., Zou, Y., Uddin, M. M., DeLeon, D., & Vancurova, I. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106093 · Cited by 22
Xie, L., Liu, M., Cai, M., Huang, W., Guo, Y., Liang, L., Cai, W., Liu, J., Liang, W., Tan, Y., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114254 · Cited by 23
Mai, S., Hodges, A., Chen, H.-M., Zhang, J., Wang, Y.-L., Liu, Y., Nakatsu, F., Wang, X., Fang, J., Xu, Y., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2483 · Cited by 21
Pannunzio, S., Bello, A. D., Occhipinti, D., Scala, A., Messina, G., Valente, G., Quirino, M., Salvatore, M. D., Tortora, G., & Cassano, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1288695 · Cited by 22
Hänze, J., Wegner, M., Noeßner, E., Hofmann, R. W., & Hegele, A. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00728-8 · Cited by 22
Pandey, S., Anang, V., & Schumacher, M. M. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.01.006 · Cited by 24
Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy
Ryba-Stanisławowska, M. E. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00992-0 · Cited by 23
Overcoming Resistance Mechanisms to Melanoma Immunotherapy
Zheng, D. X., Bozym, D. J., Tarantino, G., Sullivan, R. J., Liu, D., & Jenkins, R. W. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00907-7 · Cited by 25
Rothschilds, A. M., Tzeng, A., Mehta, N. K., Moynihan, K. D., Irvine, D. J., & Wittrup, K. D. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1558678 · Cited by 20
Dawson, N. A., Zibelman, M. R., Lindsay, T., Feldman, R. A., Saul, M. E., Gatalica, Z., Korn, W. M., & Heath, E. I. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0531 · Cited by 23
Reticker-Flynn, N. E., & Engleman, E. G. (2020) · eLife · doi:10.7554/elife.53839 · Cited by 23
A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance
Huang, Q., Lei, Y., Li, X., Guo, F., & Liu, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580140 · Cited by 22
To Vaccinate or not: Influenza Virus and Lung Cancer Progression
Angrini, M., Varthaman, A., García-Verdugo, I., Sallenave, J., Alifano, M., & Cremer, I. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.02.006 · Cited by 21
G�rard, M., Chatelain, C., Delaunay, T., Tostivint, E. P., Bennouna, J., & Fonteneau, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.695770 · Cited by 25
Nonparametric feature selection by random forests and deep neural networks
Mao, X., Peng, L., & Wang, Z. (2022) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2022.107436 · Cited by 21
El-Sayes, N., Walsh, S. R., Vito, A., Reihani, A., Ask, K., Wan, Y., & Mossman, K. L. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.03.006 · Cited by 21
van den Bosch, T., Derks, S., & Miedema, D. M. (2022) · Cancers · doi:10.3390/cancers14204986 · Cited by 21
Wang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 22
Wang, L., Yang, Z., Guo, F., Chen, Y., Wei, J., Dai, X., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1227797 · Cited by 22
Estrogen receptor regulation of the immune microenvironment in breast cancer
McGuinness, C., & Britt, K. L. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106517 · Cited by 25
Trafficking of mitochondrial double-stranded RNA from mitochondria to the cytosol
Krieger, M. R., Abrahamian, M., He, K. L., Atamdede, S., Hakimjavadi, H., Momcilovic, M., Ostrow, D. G., Maggo, S. D. S., Tsang, Y. P., Gai, X., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202302396 · Cited by 24
The added value of type I interferons to cytotoxic treatments of cancer
Bracci, L., Sistigu, A., Proietti, E., & Moschella, F. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.008 · Cited by 20
Physio-pathological effects of m6A modification and its potential contribution to melanoma
Liao, Y., Han, P., Zhang, Y., & Ni, B. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02644-3 · Cited by 20
Luo, X., Ji, X., Xie, M., Zhang, T., Wang, Y., Sun, M., Huang, W., & Xia, L. (2022) · Cancers · doi:10.3390/cancers14051165 · Cited by 20
Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells
Munari, E., Quatrini, L., Ciancaglini, C., Eccher, A., Bogina, G. S., Moretta, L., & Mariotti, F. R. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101660 · Cited by 20
Middelburg, J., Ghaffari, S., Schoufour, T. A. W., Sluijter, M., Schaap, G., Göynük, B., Sala, B. M., Al-Tamimi, L., Scheeren, F. A., Franken, K. L. M. C., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113516 · Cited by 20
Shi, H., Williams, M. J., Satas, G., Weiner, A. C., McPherson, A., & Shah, S. P. (2024) · Nature Communications · doi:10.1038/s41467-024-46710-0 · Cited by 19
Immune modulatory microRNAs as a novel mechanism to revert immune escape of tumors
Seliger, B. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.07.001 · Cited by 20
Cancer research in the era of immunogenomics
Wolf, Y., & Samuels, Y. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000475 · Cited by 20
Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review
Ye, Y., Xu, C., Chen, F., Liu, Q., & Cheng, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.771201 · Cited by 20
Haugh, A. M., Salama, A. K. S., & Johnson, D. B. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.09.005 · Cited by 20
Chen, D., Xu, L., Xuan, M., Chu, Q., & Xue, C. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1802 · Cited by 20
Connolly, E., & Hussell, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00495 · Cited by 18
Hübbe, M. L., Jæhger, D. E., Andresen, T. L., & Andersen, M. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.578349 · Cited by 20
Roberts, A., Bentley, L., Tang, T., Stewart, F., Pallini, C., Juvvanapudi, J., Wallace, G. R., Cooper, A. J., Scott, A., THICKETT, D. R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83612-3 · Cited by 21
Hwang, B.-J., Tsao, L.-C., Acharya, C. R., Trotter, T. N., Agarwal, P., Wei, J.-P., Wang, T., Yang, X., Lei, G., Osada, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003721 · Cited by 21
Hou, G., Qian, J., Wang, Y., Xu, W., Guo, M., Li, Z., Wang, J., & Suo, A. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c05580 · Cited by 19
Cao, J., Gong, Z., Liu, X., Meng, F., Sun, X., Yuan, X., Li, A., Huang, H., Wang, Y., Lu, C., et al. (2023) · ACS Materials Letters · doi:10.1021/acsmaterialslett.3c00357 · Cited by 19
Yang, R., Du, Y., Zhang, M., Liu, Y., Feng, H., Liu, R., Yang, B., Xiao, J., He, P., & Niu, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1249731 · Cited by 21
Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor
Xu, J., Chen, G., Yu, S., Yao, S., Li, W., & Cheng, H. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.10.011 · Cited by 20
Ibrahim, M. L., Zheng, H., Barlow, M. L., Latif, Y., Chen, Z., Yu, X., & Beg, A. A. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300475 · Cited by 19
Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
Li, C., Wang, Z., Yao, L., Lin, X., Jian, Y., Li, Y., Zhang, J., Shao, J., Tran, P. D., Hagman, J. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46422-5 · Cited by 22
Splitt, S. D., Souza, S. P., Valentine, K. M., Castellanos, B. E., Curd, A. B., Hoyer, K. K., & Jensen, K. D. C. (2018) · Infection and Immunity · doi:10.1128/iai.00459-18 · Cited by 19
Metadata
- Authors
- Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., Gangadhar, T. C., Amaravadi, R. K., Schuchter, L. M., Feldman, M. D., Ishwaran, H., Vonderheide, R. H., Maity, A., Wherry, E. J., & Minn, A. J.
- Affiliations
- University of Pennsylvania (US)
- University of Miami (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Minn, Andy J.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 167
- Issue
- 6
- Pages
- 1540-1554.e12
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC5385895
- OpenAlex
- W2558219863
- Cited by
- 1,216
- References
- 42
- Citations by year
- 2026: 150 · 2025: 124 · 2024: 127 · 2023: 135 · 2022: 128 · 2021: 140 · 2020: 140 · 2019: 114 · 2018: 92 · 2017: 64 · 2016: 1
- FWCI
- 48.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Apollo
- Funders
- Melanoma Research Alliance
- Parker Institute for Cancer Immunotherapy
- Robertson Foundation
- Cancer Research Institute Irvington Fellowship
- NIH (P50CA174523, R01CA163739, R01CA158186, P30CA016520, U19AI082630, R01AI105343, U01AI095608, P01AI112521)
- Basser Research Center for BRCA
- Abramson Cancer Center Translational Center of Excellence in Pancreatic Cancer
- Department of Defense Era of Hope Scholar (W81XWH-09-1-0339)
- NCI (R01CA172651)
- Merck
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint inhibitor resistance, type I interferon, interferon-gamma, PD-1 pathway, PD-L1, STAT1, interferon-stimulated genes, T cell inhibitory receptors, T cell exhaustion, radiotherapy, tumor immune microenvironment, resistance biomarkers, anti-PD-1 therapy
- MeSH terms
- Animals, Humans, Interferons, Melanoma, Neoplasm Transplantation, T-Lymphocytes, Radioimmunotherapy, Drug Resistance, Neoplasm, Cell Line, Tumor, STAT1 Transcription Factor, Mice, B7-H1 Antigen, CTLA-4 Antigen, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
